Adelphi Laboratories Retatrutide 2mg/ml – 10ml Vial
Retatrutide is a next-generation investigational peptide developed by Adelphi Laboratories, formulated at a concentration of 2mg/ml in a 10ml sterile, multi-dose vial. It is a triple agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors—designed to support advanced metabolic and obesity-related research.
No reviews yet. Be the first to share your experience.